[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529611":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":47,"collaborators":51,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":19,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":19,"enrollmentInfo":63,"targetDuration":19,"studyType":66,"phases":67,"briefSummary":70,"conditions":71,"keywords":19,"overallStatus":32,"whyStopped":19,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Azacytidine plus CAOLD regimen","EXPERIMENTAL","Patients were treated by Azacytidine plus CAOLD regimen",[13],"Drug: Azacytidine plus CAOLD regimen",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients were treated by Azacytidine(75 mg\u002Fm2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg\u002Fm2 qd d1; cytarabine 30mg\u002Fm2 qd d1-d4; vindesine 2mg\u002Fm2 qd d1; pegaspargase 2500iu\u002Fm2 qd d2; dexamethasone 7.5mg\u002Fm2 qd d1-d5)",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Liren Qian, PhD","STUDY_CHAIR",[25],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","+861066957676","qlr2007@126.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Navy General Hospital","RECRUITING","Beijing","Beijing Municipality","100048","China","CN",{"type":39,"coordinates":40},"Point",[41,42],116.39723,39.9075,{"lat":42,"lon":41},[45],{"name":46,"role":26,"phone":27,"phoneExt":19,"email":28},"Liren Qian, M.D.",{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Liren Qian","Associate Chief Physician, Associate Professor",[52],{"name":53,"class":6},"Chinese PLA General Hospital","100529611","phase-1-azacytidine-plus-caold-regimen-in-relapsedrefractory-peripheral-t-cell-lymphomas-100529611",false,"NCT06176027","Azacytidine Plus CAOLD Regimen in Relapsed\u002FRefractory Peripheral T-Cell Lymphomas","Therapeutic Effect of Chemotherapy Azacytidine Plus CAOLD Regimen on Patients With Relapsed\u002FRefractory Peripheral T-Cell Lymphomas","Inclusion Criteria:\n\nPatients must satisfy all following criteria to be enrolled in the study:\n\n* Pathologically confirmed angioimmunoblastic T-cell lymphoma according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Relapsed (after partial or complete response) or refractory AITL after at least one line of systemic therapy (there is no mandatory resting period after the previous treatment as long as the biochemistry and hematology labs meet the inclusion criteria as below.)\n* Meet the following lab criteria:\n\n  * Absolute Neutrophil Count (ANC) ≥ 1,5 x 10\\^9\u002FL (≥ 1 x 10\\^9\u002FL if bone marrow (BM) involvement by lymphoma)\n  * Platelet ≥ 75 x 10\\^9\u002FL (≥ 50 x 10\\^9\u002FL if BM involvement by lymphoma)\n  * Hemoglobin ≥ 8 g\u002FdL.\n* Anticipated life expectancy at least 3 months\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy;\n* Pregnant or lactating women","ALL","18 Years",{"count":64,"type":65},52,"ESTIMATED","INTERVENTIONAL",[68,69],"PHASE1","PHASE2","This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with CAOLD Regimen in the treatment of relapsed\u002Frefractory peripheral t-cell lymphomas.",[72,73],"Relapsed Peripheral T-Cell Lymphomas","Refractory Peripheral T-Cell Lymphomas","2024-10-26",{"date":76,"type":77},"2024-10-29","ACTUAL",{"date":79,"type":77},"2024-10-01",{"date":81,"type":65},"2030-09-01",{"name":5,"class":6},1]